Elotuzumab Approved in Europe for Multiple Myeloma

The European Commission approved elotuzumab (Empliciti) for use in combination with lenalidomide (Revlimid) and dexamethasone for patients with multiple myeloma following progression on at least 1 prior therapy.
Source: International Myeloma Foundation - Category: Hematology Source Type: news